Stock Events

Stock Events

Shield Therapeutics 

€0.034500
46
-€0.00-5.48%Friday 20:47

Statistics

Day High
0.037
Day Low
0.0345
52W High
0.15
52W Low
0.0325
Volume
-
Avg. Volume
-
Mkt Cap
36.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 20Expected
Q2 2025
Q2 2026
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
0

Financials

-35.5%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
42.28MRevenue
-15.01MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1JS.STU. It's not an investment recommendation.
Legal & General Group
11
LGEN.LSE
Lloyds Banking Group
9
LLOY.LSE
National Grid
8
NG.LSE
GSK
8
GSK.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap251.94B
Amgen develops treatments in areas similar to Shield Therapeutics, including anemia which directly competes with Shield's Feraccru/Iron product.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes in the pharmaceutical space with products that could serve as alternatives to treatments offered by Shield Therapeutics, especially in gastrointestinal and chronic conditions.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca operates in similar therapeutic areas as Shield, including treatments for anemia and other conditions that Shield's products address.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, offers a wide range of products that compete across the board with Shield's portfolio, including anemia and chronic disease treatments.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline has a broad portfolio that includes treatments for conditions like anemia, competing with Shield's main product offerings.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a diverse drug portfolio that includes treatments in areas competing with Shield Therapeutics, particularly in chronic diseases and conditions treated by Shield's products.
Novartis
NVS
Mkt Cap303.67B
Novartis offers a wide range of pharmaceutical products, including those for anemia and chronic conditions, directly competing with Shield Therapeutics' market.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb competes in the global pharmaceutical market with a focus on serious diseases, including areas that overlap with Shield Therapeutics' focus areas.
Merck
MRK
Mkt Cap368.89B
Merck operates in various therapeutic areas, including those that compete with Shield Therapeutics, offering alternative treatments for conditions like anemia.
Sanofi
SNY
Mkt Cap106.24B
Sanofi produces a range of pharmaceutical products that compete with Shield Therapeutics, especially in the chronic disease treatment space.

About

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Show More
CEO
Anders Lundstrom
Employees
61
Country
United Kingdom
ISIN
GB00BYV81293
WKN
000A2AE98

Listings

F
DE
1JS.F
STU
DE
1JS.STU
LSE
GB
STX.LSE
OTC Link
US
SHIEF

0 Comments

Share your thoughts

FAQs

What is Shield Therapeutics stock price today?▼
The current price of 1JS.STU is €0.03 EUR — it has decreased by -5.48% in the past 24 hours. Watch Shield Therapeutics stock price performance more closely on the chart.
What is Shield Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Shield Therapeutics stocks are traded under the ticker 1JS.STU.
Is Shield Therapeutics stock price growing?▼
1JS.STU stock has fallen by -46.09% compared to the previous week, the month change is a -41.53% fall, over the last year Shield Therapeutics has showed a -42.98% decrease.
What is Shield Therapeutics market cap?▼
Today Shield Therapeutics has the market capitalization of 36.91M
When is the next Shield Therapeutics earnings date?▼
Shield Therapeutics is going to release the next earnings report on April 29, 2027.
What were Shield Therapeutics earnings last quarter?▼
1JS.STU earnings for the last quarter are 0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Shield Therapeutics revenue for the last year?▼
Shield Therapeutics revenue for the last year amounts to 42.28M EUR.
What is Shield Therapeutics net income for the last year?▼
1JS.STU net income for the last year is -15.01M EUR.
How many employees does Shield Therapeutics have?▼
As of November 8, 2026, the company has 61 employees.
In which sector is Shield Therapeutics located?▼
Shield Therapeutics operates in the Health & Wellness sector.
When did Shield Therapeutics complete a stock split?▼
Shield Therapeutics has not had any recent stock splits.
Where is Shield Therapeutics headquartered?▼
Shield Therapeutics is headquartered in Gateshead, United Kingdom.